Logo image of ATAI

ATAI LIFE SCIENCES NV (ATAI) Stock Fundamental Analysis

NASDAQ:ATAI - Nasdaq - NL0015000DX5 - Common Stock - Currency: USD

2.72  +0.1 (+3.82%)

Premarket: 2.71 -0.01 (-0.37%)

Fundamental Rating

2

Taking everything into account, ATAI scores 2 out of 10 in our fundamental rating. ATAI was compared to 193 industry peers in the Pharmaceuticals industry. While ATAI seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ATAI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATAI had negative earnings in the past year.
ATAI had a negative operating cash flow in the past year.
In the past 5 years ATAI always reported negative net income.
ATAI had a negative operating cash flow in each of the past 5 years.
ATAI Yearly Net Income VS EBIT VS OCF VS FCFATAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ATAI (-76.24%) is worse than 70.47% of its industry peers.
The Return On Equity of ATAI (-98.17%) is worse than 60.10% of its industry peers.
Industry RankSector Rank
ROA -76.24%
ROE -98.17%
ROIC N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ATAI Yearly ROA, ROE, ROICATAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATAI Yearly Profit, Operating, Gross MarginsATAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATAI has more shares outstanding
The number of shares outstanding for ATAI has been increased compared to 5 years ago.
ATAI has a worse debt/assets ratio than last year.
ATAI Yearly Shares OutstandingATAI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
ATAI Yearly Total Debt VS Total AssetsATAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.58, we must say that ATAI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ATAI (1.58) is better than 62.18% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that ATAI is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.06, ATAI is in line with its industry, outperforming 52.85% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 1.58
ROIC/WACCN/A
WACC7.24%
ATAI Yearly LT Debt VS Equity VS FCFATAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ATAI has a Current Ratio of 4.07. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ATAI (4.07) is better than 62.18% of its industry peers.
A Quick Ratio of 4.07 indicates that ATAI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.07, ATAI is in the better half of the industry, outperforming 64.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 4.07
ATAI Yearly Current Assets VS Current LiabilitesATAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

ATAI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -264.00%.
ATAI shows a decrease in Revenue. In the last year, the revenue decreased by -1.91%.
Measured over the past years, ATAI shows a very negative growth in Revenue. The Revenue has been decreasing by -75.28% on average per year.
EPS 1Y (TTM)-264%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATAI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.22% yearly.
Based on estimates for the next years, ATAI will show a very strong growth in Revenue. The Revenue will grow by 289.39% on average per year.
EPS Next Y47.9%
EPS Next 2Y20.42%
EPS Next 3Y15.19%
EPS Next 5Y30.22%
Revenue Next Year184.92%
Revenue Next 2Y-37.82%
Revenue Next 3Y366.01%
Revenue Next 5Y289.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ATAI Yearly Revenue VS EstimatesATAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ATAI Yearly EPS VS EstimatesATAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATAI Price Earnings VS Forward Price EarningsATAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATAI Per share dataATAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ATAI's earnings are expected to grow with 15.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.42%
EPS Next 3Y15.19%

More info and screens

0

5. Dividend

5.1 Amount

ATAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATAI LIFE SCIENCES NV

NASDAQ:ATAI (7/14/2025, 8:23:52 PM)

Premarket: 2.71 -0.01 (-0.37%)

2.72

+0.1 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners10.13%
Inst Owner Change0%
Ins Owners2.84%
Ins Owner Change28.14%
Market Cap577.02M
Analysts83.08
Price Target8.98 (230.15%)
Short Float %5.28%
Short Ratio2.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.56%
Min EPS beat(2)-62.27%
Max EPS beat(2)17.15%
EPS beat(4)1
Avg EPS beat(4)-40.11%
Min EPS beat(4)-115.21%
Max EPS beat(4)17.15%
EPS beat(8)5
Avg EPS beat(8)12.3%
EPS beat(12)7
Avg EPS beat(12)7.19%
EPS beat(16)9
Avg EPS beat(16)-10.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10%
PT rev (3m)10%
EPS NQ rev (1m)4%
EPS NQ rev (3m)35.14%
EPS NY rev (1m)29.63%
EPS NY rev (3m)36.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-20.05%
Revenue NY rev (3m)215.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1873.44
P/FCF N/A
P/OCF N/A
P/B 3.79
P/tB 3.88
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS0.72
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.24%
ROE -98.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1007.92%
Cap/Sales 1983.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.07
Quick Ratio 4.07
Altman-Z 1.58
F-Score3
WACC7.24%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-264%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y47.9%
EPS Next 2Y20.42%
EPS Next 3Y15.19%
EPS Next 5Y30.22%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year184.92%
Revenue Next 2Y-37.82%
Revenue Next 3Y366.01%
Revenue Next 5Y289.39%
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.66%
EBIT Next 3Y-10.22%
EBIT Next 5Y6.19%
FCF growth 1Y18.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.51%
OCF growth 3YN/A
OCF growth 5YN/A